viewNanoveu Ltd

Nanoveu fills first antiviral product sales orders, on track for first revenue in quarter three

The company is confident of strong demand for its products, with orders from customers across the US, UK, Asia and Australia.

Nanoveu Ltd - Nanoveu fills first antiviral product sales orders, on track for first revenue in quarter three
Nanoveu is set meet its guidance of first revenues in early quarter three 2020

Nanoveu Ltd (ASX:NVU) is trading higher upon completing its inaugural production run and filling the first sales orders for its antiviral protection products.

Antiviral products have been despatched to AIBI Pte Ltd, a Singapore-based fitness equipment and wellness provider to the Asia-Pacific region and which is a distributor of Nanoveu’s antiviral products.

Nanoveu has also filled first orders from customers in other key international markets, including the US, UK and Australia for incorporation of its protection technology into several different applications including for benchtops, computer screens and touchscreen surfaces.

Shares in the company have been as much as 35% higher to 8.3 cents intra-day.

“Global distribution network”

Nanoveu executive chairman and CEO Alfred Chong said: “It is exceptionally exciting to see the first shipment of our product into major international markets.

“We are continuing to build a global distribution network for our technology.

“Nanoveu continues to expedite its mobile phone protection product but is also taking advantage of strong take-up of commercial-sized sheets of anti-viral film which our distributors are looking to use for many expanding applications.”

The initial despatch of its antiviral products will see Nanoveu meet its guidance of first revenues in early quarter three of 2020.

Antiviral technology

Nanoveu’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses, proven to eliminate 99.99% of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes.

The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2) and coronavirus MHV-A592.

Keywest kiosks

Keywest Technology, a US-based B2B supplier, has purchased Nanoveu’s antiviral product and intends to apply the film on several shopping centre digital kiosks.

This company's CEO and president Kyott Nichol said: “Keywest Technology has been bringing digital devices and information kiosks to America for more than two decades and we have never seen a situation where customers have so clearly demanded additional protection at touchpoints and digital displays.

“We are proud to be making a proactive step in partnership with Nanoveu to implement antiviral protection and offer peace of mind to consumers.”

Quick facts: Nanoveu Ltd

Price: 0.06 AUD

Market: ASX
Market Cap: $9.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nanoveu Ltd named herein, including the promotion by the Company of Nanoveu Ltd in any Content on the Site, the Company receives from said...


Nanoveu focused on commercialising EyeFyx product following 'revolutionary'...

Nanoveu Ltd's (ASX:NVU) Alfred Chong caught up with Proactive's Andrew Scott after completing what they describe as a revolutionary advanced prototype of its EyeFyx product. It's designed to correct farsightedness for people using digital devices without the need for glasses. The company has...

on 18/11/20

2 min read